The Influence of Hydro-Alcoholic Media on Drug Release - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Influence of Hydro-Alcoholic Media on Drug Release
The authors investigate the influence of hydro-alcoholic media on hydration and drug release from polyethylene oxide extended-release matrices.

Pharmaceutical Technology
Volume 35, Issue 7, pp. 50-58


Extended-release PEO tablets of the practically water insoluble drug gliclazide (30 mg) and freely soluble metformin HCl (500 mg) retained their hydrated structural integrity when exposed to 5% and 40% w/v ethanol solutions for up to 12 h. The matrices did not fail in hydro-alcoholic media. Small differences in drug release profiles were explained in terms of drug solubility in various media. The results of this study identified trends similar to those in previously published data for HPMC ER matrix systems.

Exposure of compacts of three different viscosity grades of PEO (Polyox 1105, 301, and Coagulant) to water or hydro-alcoholic solutions had shown gradual swelling and gelation without any disruption to the tablet integrity. The compact wet weight appeared to be only slightly lower in hydro-alcoholic solutions compared to water. The extent of their relative swelling was found to increase with increasing molecular weight of PEO from 900,000 Da to 5,000,000 Da. No significant difference in compact relative swelling was observed when MW increased further from 4,000,000 Da (Polyox 301) to 5,000,000 Da (Polyox Coagulant).

This study clearly indicates that PEO matrices produces consistent drug release in water and in hydro-alcoholic media with no signs of a potential dose dumping.

Marina Levina, PhD,* is senior manager, product development at Colorcon Limited,
, +44 (1) 322-627321. Dasha Palmer is product development scientist, Thomas P. Farrell, PhD, is director, product development, and Ali R. Rajabi-Siahboomi, PhD, is director of scientific affairs, all at Colorcon in Dartford, England.

*To whom all correspondence should be addressed.

Submitted: Feb. 17, 2011. Accepted: Apr. 5, 2011.


1. M. Levina and A.R. Rajabi-Siahboomi, J. Pharm. Sci. 93 (11) 2746–2754 (2004).

2. S.U. Choi, J. Lee, and Y.W. Choi, Drug. Dev. Ind. Pharm. 29 (10) 1045–1052 (2003).

3. H. Li, R.J. Hardy, and X. Gu, AAPS. PharmSci. 9 (2) 437–443 (2008).

4. R.L. Davidson, Handbook of Water-Soluble Gums and Resins (McGraw-Hill, New York, NY, 1980).

5. N.B. Graham and M.E. McNeil, Biomaterials. 5 (1) 27–36 (1984).

6. A. Apicella et al., Biomaterials. 14 (2) 83–91 (1993).

7. J.W. Moore and H.H. Flanner, Pharm. Technol. 20 (6) 64–74 (1996).

8. L. Yang, G. Venkatesh, and R. Fassihi, J. Pharm. Sci. 85 (10) 1085–1090 (1996).

9 F. Zhang and J.W. McGinity, Pharm. Dev. Technol. 4 (2) 241–250 (1999).

10. A.M. Razaghi and J.B. Schwartz, Drug. Dev. Ind. Pharm. 28 (6) 695–701 (2002).

11. S. Dhawan, M. Varma, and V.R. Sinha, Pharm. Technol. 29 (5) 72–79 (2005).

12. S. Dhawan, K. Dhawan and V.R. Sinha, Pharm. Technol. 29 (5) 82–96 (2005).

13. M. Levina, A. Gothoskar, and A.R. Rajabi-Siahboomi, Pharm. Technol. Eur. 18 (7) 20–26 (2006).

14. Handbook of Pharmaceutical Excipients, 3rd ed., R.C. Rowe, P.J. Sheskey, and M.E. Quinn, Eds. (Pharmaceutical Press, London, 2009).

15. L. Maggi, R. Bruni, and U. Conte, Int. J. Pharm. 195 (1-2) 229–238 (2000).

16. J. Siepmann and N.A. Peppas, Adv. Drug. Deliv. Rev. 48 (2–3) 139–157 (2001).

17. M. Levina, D. Palmer, and A.R. Rajabi-Siahboomi, Drug. Del. Tech. 10 (5) 18–23 (2010).

18. M. Levina, H. Vuong, and A.R Rajabi-Siahboomi, Drug. Dev. Ind. Pharm. 33 () 1125–1134 (2007).

19. National Health Service, "Statistics on Alcohol: England" (NHS, UK, 2009),, accessed Sept. 2010.

20. M.K. Serdula et al., Am. J. Prev. Med. 26 (4) 294–298 (2004).

21. W. Roth et al., Int. J. Pharm. 368 (1-2) 72–75 (2009).

22. B. Skalsky et al., presentation at the 34th Annual Meeting and Exposition of the Controlled Release Society (Long Beach, CA, 2007).

23. A. Makin and R. William, Q. J. Med. 93 (6) 341–349 (2000).

24. FDA, "FDA ALERT [7/2005]: Alcohol-Palladone Interaction," (Rockville, MD, 2005).

25. H.M. Fadda, Y. AlBasarah, and A. Basit, presentation at the AAPS Annual Meeting and Exposition (San Antonio, TX, 2006).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here